Bio-evidence Science Academy (BSA), Xi'an Jiaotong University (XJTU), No. 205 Zhuque Street, Xi'an 710061, China; Key laboratory of Ministry of Public Health for Forensic Sciences, No. 205 Zhuque Street, Xi'an 710061, China.
National & Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, Precision Medical Institute, Institute of Digestive Diseases. The Second Affiliated Hospital, Xi'an Jiaotong University, No. 157 West 5th Road, Xi'an 710004, China.
Int Immunopharmacol. 2021 Jan;90:107222. doi: 10.1016/j.intimp.2020.107222. Epub 2020 Dec 1.
This article explores the role of ApoA4 in a CCl-induced chronic liver injury (CLI) mouse model. C57BL/6J mice (WT) and ApoA4 knock-out (KO) mice were divided into CCl CLI (WT-CCl and KO-CCl) and olive oil solvent control groups (WT-Veh and KO-Veh). Some of the KO-CCl mice were additionally treated with recombinant mouse ApoA4 and primary mouse T lymphocyte injections. After 6 weeks, histological analyses, biochemical and superoxide dismutase (SOD) and malondialdehyde (MDA) assays, flow cytometry of immune cells and qRT-PCR analyses were performed. KO mice after treatment with CCl showed reduced hepatic SOD and enhanced serum MDA activities leading to worsening liver injury and fibrosis compared with WT-CCl, accompanied by enhanced hepatic alpha smooth muscle actin (α-SMA), tissue inhibitor of metalloproteinases-1 (TIMP-1) and collagen type I alpha 1 chain (COL1A1) transcriptions, elevated macrophage M1 levels, enhanced tumor necrosis factor-alpha (TNF-α), Interleukin 6 (IL-6) and C-C Motif Chemokine Ligand 5 (CCL5), but reduced Interleukin 10 (IL-10), monocyte chemotactic protein 1 (MCP-1), C-C Motif Chemokine Receptor 2 (CCR2), C-X3-C Motif Chemokine Receptor 1 (CX3CR1) and C-X-C Motif Chemokine Ligand 9 (CXCL9) transcription, as well as reduced CD3+, CD4+ and CD8+ T cell percentages in hepatic tissue, blood cells and spleen. In addition, CD11b+CD115+, CD11b+/Ly6C, CD11b+/LyC6 and CD11b+/Ly6C cells were enhanced, which partly reversed by ApoA4 protein and T cell injections. In conclusion, we propose that ApoA4 might be involved in liver protection via inhibiting fibrotic mediators and inflammatory cytokines, suppression of pro-inflammatory hepatic M1 cell invasion and regulation of CD8+ T and CD4+ T lymphocytes.
本文探讨了载脂蛋白 A4(ApoA4)在 CCl 诱导的慢性肝损伤(CLI)小鼠模型中的作用。将 C57BL/6J 小鼠(WT)和 ApoA4 敲除(KO)小鼠分为 CCl CLI(WT-CCl 和 KO-CCl)和橄榄油溶剂对照组(WT-Veh 和 KO-Veh)。部分 KO-CCl 小鼠还接受了重组鼠 ApoA4 和原代鼠 T 淋巴细胞注射治疗。6 周后,进行组织学分析、生化和超氧化物歧化酶(SOD)和丙二醛(MDA)测定、免疫细胞流式细胞术和 qRT-PCR 分析。与 WT-CCl 相比,用 CCl 处理的 KO 小鼠的肝 SOD 降低,血清 MDA 活性增强,导致肝损伤和纤维化加重,伴有肝α平滑肌肌动蛋白(α-SMA)、金属蛋白酶组织抑制剂 1(TIMP-1)和胶原 I 型α1 链(COL1A1)转录增强,巨噬细胞 M1 水平升高,肿瘤坏死因子-α(TNF-α)、白细胞介素 6(IL-6)和 C-C 基序趋化因子配体 5(CCL5)升高,而白细胞介素 10(IL-10)、单核细胞趋化蛋白 1(MCP-1)、C-C 基序趋化因子受体 2(CCR2)、C-X3-C 基序趋化因子受体 1(CX3CR1)和 C-X-C 基序趋化因子配体 9(CXCL9)转录降低,肝组织、血细胞和脾脏中 CD3+、CD4+和 CD8+T 细胞百分比降低。此外,CD11b+CD115+、CD11b+/Ly6C、CD11b+/LyC6 和 CD11b+/Ly6C 细胞增加,这些细胞的增加部分可通过 ApoA4 蛋白和 T 细胞注射逆转。总之,我们提出 ApoA4 可能通过抑制纤维化介质和炎症细胞因子、抑制促炎肝 M1 细胞浸润以及调节 CD8+T 和 CD4+T 淋巴细胞来参与肝脏保护。